Melvin Simien, MD
Gastroenterology · Fort Worth, TXNPI 1114152048
Payments from drug & device makers
Across 194 payments — averaging $78.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Creo Medical Inc.$6K
- Boston Scientific$5K
- AbbVie$1K
- Medtronic$434
- Lumendi LLC$334
- Endogastric Solutions, Inc$315
- plus $2K from 33 others
What the payments were for
- Consulting fees$3,20021%
- Speaking & faculty fees$6754%
- Travel & lodging$4,03427%
- Food & beverage$7,25348%
- Entertainment$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Creo Medical Inc. | 11 | $6,167 |
| Boston Scientific | 51 | $4,534 |
| AbbVie | 31 | $1,192 |
| Medtronic | 4 | $434 |
| Lumendi LLC | 6 | $334 |
| Endogastric Solutions, Inc | 7 | $315 |
| Johnson & Johnson(3 entities) | 8 | $238 |
| Cook Medical LLC | 2 | $213 |
| Ambu Inc. | 2 | $179 |
| Lilly USA, LLC | 8 | $144 |
| Nestle Healthcare Nutrition Inc. | 2 | $133 |
| Evoke Pharma, Inc. | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $121 |
| Braintree Laboratories, Inc. | 6 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $97 |
| Phathom Pharmaceuticals, Inc. | 5 | $81 |
| Bristol Myers Squibb | 4 | $75 |
| Laborie Medical Technologies Corp. | 2 | $69 |
| QOL Medical, LLC | 3 | $66 |
| Merck | 4 | $64 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| UCB, Inc. | 2 | $42 |
| Pfizer | 2 | $41 |
| Apollo Endosurgery US Inc | 2 | $40 |
| Ferring Pharmaceuticals Inc. | 2 | $35 |
| Sandoz | 2 | $31 |
| Conmed Corporation | 1 | $31 |
| Alcresta Therapeutics, Inc. | 1 | $29 |
| Amgen | 1 | $27 |
| Aurinia Pharma U.S., Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $22 |
| Sanofi | 1 | $22 |
| Ardelyx, Inc. | 1 | $21 |
| Enterra Medical, Inc. | 1 | $19 |
| Celltrion USA Inc. | 1 | $15 |
| Olympus America Inc. | 1 | $13 |
| Covidien LP | 1 | $13 |
| Redhill Biopharma Inc. | 1 | $12 |
| Mauna Kea Technologies, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Speedboat Ultraslim (SB1L)$5,046
- SPEEDBOAT$1,084
- EXALT Model D$1,015
- GENERAL - THERAPIES$586
- Skyrizi$468
- Resolution 360 Clip$385
- ACQUIRE$317
- ORISE$301
- Digitrapper$210
- ProdiGI$161
- GENERAL - METAL STENTS - G.I.$148
- OverStitch Endoscopic Suturing System$140
- APOLLO ESG System$128
- Instinct$128
- GIMOTI$125
- GENERAL HEMOSTASIS$122
- ZENPEP$119
- ESOPHYX$119
- Humira$113
- GENERAL - BILIARY DEVICES$109
How this compares
$15,174 in reported general payments places this provider in the 80th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 19 | $18,834 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 19 | $2,601 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 18 | $1,026 |
| Pantoprazole Sodium | 90 | $699 |
| Esomeprazole Magnesium | 14 | $695 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 21 | $262 |
| Dicyclomine Hcl | 18 | $244 |
| Omeprazole | 13 | $154 |
| Famotidine | 11 | $94 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $1,192 | $18,83419 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $97 | $2,60119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Fort Worth
- Eric LawitzSan Antonio$59.5M
- George DuvallTyler$17.5M
- John FordtranDallas$9.9M
- Timothy RitterSouthlake$7.7M
- Parvez MantryDallas$6.4M
- Mazen NoureddinHouston$6.1M
- Nadege GunnWaco$5.7M
- Michael BrownDallas$5.5M
- James MaherHouston$5.3M
- Stephen HarrisonLive Oak$5.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.